These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29261249)

  • 1. Real-world economic value of a 21-gene assay in early-stage breast cancer.
    Waintraub SE; McNamara D; Graham DMA; Pecora AL; Min J; Wu T; Noh HG; Connors J; Pe Benito R; Choi K; Schultz E; Goldberg SL
    Am J Manag Care; 2017 Dec; 23(12):e416-e420. PubMed ID: 29261249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
    Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
    J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.
    Epstein AJ; Wong YN; Mitra N; Vachani A; Hin S; Yang L; Smith-McLallen A; Armstrong K; Groeneveld PW
    J Clin Oncol; 2015 Dec; 33(36):4259-67. PubMed ID: 26598749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
    Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
    Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
    Yang M; Rajan S; Issa AM
    Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
    Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
    JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.
    Hannouf MB; Zaric GS; Blanchette P; Brezden-Masley C; Paulden M; McCabe C; Raphael J; Brackstone M
    Pharmacogenomics J; 2020 Feb; 20(1):27-46. PubMed ID: 31130722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.
    Potosky AL; O'Neill SC; Isaacs C; Tsai HT; Chao C; Liu C; Ekezue BF; Selvam N; Kessler LG; Zhou Y; Schwartz MD
    Cancer; 2015 Nov; 121(22):4062-70. PubMed ID: 26291519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.
    Smyth L; Watson G; Walsh EM; Kelly CM; Keane M; Kennedy MJ; Grogan L; Hennessy BT; O'Reilly S; Coate LE; O'Connor M; Quinn C; Verleger K; Schoeman O; O'Reilly S; Walshe JM
    Breast Cancer Res Treat; 2015 Oct; 153(3):573-82. PubMed ID: 26364296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
    Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential economic impact of the 21-gene expression assay on the treatment of breast cancer in Brazil.
    Bacchi CE; Prisco F; Carvalho FM; Ojopi EB; Saad ED
    Rev Assoc Med Bras (1992); 2010; 56(2):186-91. PubMed ID: 20498993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.
    Yamauchi H; Nakagawa C; Yamashige S; Takei H; Yagata H; Yoshida A; Hayashi N; Hornberger J; Yu T; Chao C; Yoshizawa C; Nakamura S
    BMC Health Serv Res; 2014 Sep; 14():372. PubMed ID: 25190451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.
    Mittmann N; Earle CC; Cheng SY; Julian JA; Rahman F; Seung SJ; Levine MN
    J Clin Oncol; 2018 Jan; 36(3):238-243. PubMed ID: 29193984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use and Costs for Tumor Gene Expression Profiling Panels in the Management of Breast Cancer From 2006 to 2012: Implications for Genomic Test Adoption Among Private Payers.
    Roberts MC; Dusetzina SB
    J Oncol Pract; 2015 Jul; 11(4):273-7. PubMed ID: 26105668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
    Dinan MA; Wilson LE; Reed SD
    J Natl Compr Canc Netw; 2019 Mar; 17(3):245-254. PubMed ID: 30865923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer.
    Garrison LP; Babigumira JB; Masaquel A; Wang BC; Lalla D; Brammer M
    Value Health; 2015 Jun; 18(4):541-6. PubMed ID: 26091608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
    Lux MP; Nabieva N; Hildebrandt T; Rebscher H; Kümmel S; Blohmer JU; Schrauder MG
    Breast; 2018 Feb; 37():89-98. PubMed ID: 29128582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients.
    Marino P; Siani C; Bertucci F; Roche H; Martin AL; Viens P; Seror V
    Breast Cancer Res Treat; 2011 Sep; 129(2):401-9. PubMed ID: 21061059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.